idelalisib + rituximab + bendamustine

**Idelalisib + rituximab + bendamustine** is a three-drug combination regimen used primarily in the management of relapsed or refractory chronic lymphocytic leukemia (CLL) and certain indolent non-Hodgkin lymphomas (iNHL). Idelalisib is a selective small molecule inhibitor of phosphatidylinositol 3-kinase delta (PI3Kδ), disrupting critical B-cell signaling pathways essential for malignant B-cell survival and proliferation. Rituximab is a chimeric monoclonal antibody targeting CD20 on B cells, inducing cell lysis through immune-mediated mechanisms. Bendamustine is a bifunctional alkylating agent that induces cytotoxic DNA damage in proliferating lymphocytes. The combination aims to maximize antitumor efficacy by attacking malignant B cells through distinct yet complementary mechanisms, and has demonstrated higher response rates and longer progression-free survival than chemoimmunotherapy alone, albeit with increased risk of severe adverse events, including infections and hematologic toxicity[2][3][4][5]. This regimen is not a fixed-dose commercial product but a protocol-driven combination of three separately available agents.

Brand names

Zydelig (for idelalisib)Treanda (for bendamustine)Rituxan (for rituximab)idelalisib + bendamustine + rituximab

Other names

IBR regimen